AustCancer Names PondelWilkinson as Strategic Investor Relations and Corporate Communications Counsel.

SYDNEY, Australia -- Australian Cancer Technology ("AustCancer") (ASX:ACU), today said that it has appointed PondelWilkinson Inc. as its agency of record for investor relations and corporate communications counsel.

"The addition of a U.S.-based specialty communications firm like PondelWilkinson dovetails with our imminent plans to move the company's headquarters in early 2005 from Sydney to San Diego, California, one of the nation's biotech epicenters," said Paul Hopper, the company's Managing Director. "The firm has more than three decades of strategic corporate and investor relations experience, with particular expertise in the healthcare and biotechnology sectors, and we look forward to working with their senior team to enhance and build our profile in the United States."

PondelWilkinson Inc., a national investor relations and financial communications advisory firm, provides strategic investor relations counsel, including direct liaison with Wall Street; financial and business news media relations; and M&A, crisis communications and litigation support. Founded in 1968 and under the current management since 1981, the firm also provides business development communications services for financial and professional services firms. PondelWilkinson is headquartered in Los Angeles, with offices and affiliates in New York, Boston and Portland, Oregon.

About Australian Cancer Technology (www.austcancer.com.au)

Australian Cancer Technology (ASX:ACU) is a broadly based international oncology company developing a portfolio of high quality oncology-related projects that are at various stages of commercialization. Its leading edge Pentrys(TM) anti-cancer vaccine successfully completed Phase I and Phase I/IIa trials at St. Vincent's Hospital Sydney and is undergoing a comprehensive Phase IIb trial with prostate cancer patients at three leading Melbourne institutions. Its US subsidiary, revisys(TM), has released a range of medical nutritionals designed by leading US scientists for people with special needs, including those undergoing cancer treatments. The company acquired the US based Galenica Pharmaceuticals (renamed Adjuvantys(TM)), whose immune enhancing adjuvants are being used in three Phase I and II cancer trials and will be used in a number of other forthcoming clinical trials in association with Memorial Sloan Kettering Cancer Centre in New York. AustCancer recently acquired the North American license for the promising pancreatic cancer drug, RP101, for which it is developing an accelerated clinical trial program including application to the US FDA for Orphan Drug status. The company is also collaborating with the US company, Bioaccelerate Inc on the development of a prostate cancer drug which is expected to go into clinical trials in 2005. AustCancer has established a Level 1 ADR stock program in the US, trading under the code of AUCJY, and has undertaken a secondary listing on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange, trading under the code CBS.